Transcriptomic biomarkers for individual risk assessment in new onset heart failure

Abstract

A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.

1 - 55 . (canceled) 
     
     
         56 . A composition comprising a set of labeled nucleic acid molecules derived from a patient with heart failure wherein the labeled nucleic acid molecules comprises nucleic acid molecules that correspond to HSPG2, CRIP2, TNFRSF14, LOC23117, OBSL1, SLC26A10, PDDC1, RERE, C18orf1, LOC401320, CUGBP2, RBM5, NKTR, SEMA3B, RBMS1, ABCD4, MYH6, MYH7, SFRS16, CA4, EXOSC10, ATXN2L, LTBP4, PTGER3, GPATCH8, LRRC37A, DDX27, SETD5, LONP2, LUC7L, RASA3, MRPS9, RBMS1, CHES1, ZDHHC1, and ARHGAP26. 
     
     
         57 . The composition of  claim 56 , wherein the labeled nucleic acid molecules are hybridized with a microarray. 
     
     
         58 . The composition of  claim 56 , wherein the labeled nucleic acid molecules is amplified nucleic acid molecules. 
     
     
         59 . The composition of  claim 58 , wherein the amplified nucleic acid molecules is amplified by RT-PCR. 
     
     
         60 . The composition of  claim 56 , wherein the labeled nucleic acid molecules independently hybridize to sequences that correspond to HSPG2, CRIP2, TNFRSF14, LOC23117, OBSL1, SLC26A10, PDDC1, RERE, C18orf1, LOC401320, CUGBP2, RBM5, NKTR, SEMA3B, RBMS1, ABCD4, MYH6, MYH7, SFRS16, CA4, EXOSC10, ATXN2L, LTBP4, PTGER3, GPATCH8, LRRC37A, DDX27, SETD5, LONP2, LUC7L, RASA3, MRPS9, RBMS1, CHES1, ZDHHC1, and ARHGAP26. 
     
     
         61 . The composition of  claim 56 , wherein the labeled nucleic acid molecules are labeled DNA. 
     
     
         62 . The composition of  claim 56 , wherein the labeled nucleic acid molecules are labeled cDNA. 
     
     
         63 . The composition of  claim 56 , wherein the labeled nucleic acid molecules consists of nucleic acid molecules that correspond to HSPG2, CRIP2, TNFRSF14, LOC23117, OBSL1, SLC26A10, PDDC1, RERE, C18orf1, LOC401320, CUGBP2, RBM5, NKTR, SEMA3B, RBMS1, ABCD4, MYH6, MYH7, SFRS16, CA4, EXOSC10, ATXN2L, LTBP4, PTGER3, GPATCH8, LRRC37A, DDX27, SETD5, LONP2, LUC7L, RASA3, MRPS9, RBMS1, CHES1, ZDHHC1, and ARHGAP26. 
     
     
         64 . A method of generating labeled nucleic acid molecules, the method comprising, labeling nucleic acid molecules derived from an endomyocardial biopsy sample that correspond to HSPG2, CRIP2, TNFRSF14, LOC23117, OBSL1, SLC26A10, PDDC1, RERE, C18orf1, LOC401320, CUGBP2, RBM5, NKTR, SEMA3B, RBMS1, ABCD4, MYH6, MYH7, SFRS16, CA4, EXOSC10, ATXN2L, LTBP4, PTGER3, GPATCH8, LRRC37A, DDX27, SETD5, LONP2, LUC7L, RASA3, MRPS9, RBMS1, CHES1, ZDHHC1, and ARHGAP26. 
     
     
         65 . The method of  claim 64 , further comprising performing RT-PCR on the endomyocardial biopsy sample prior to labeling the nucleic acid molecules. 
     
     
         66 . The method of  claim 64 , wherein the nucleic acid molecules are labeled with a radioisotope label, a fluorescent label, or an enzyme label. 
     
     
         67 . The method of  claim 64 , wherein the labeled nucleic acid molecules are label DNA. 
     
     
         68 . The method of  claim 64 , wherein the labeled nucleic acid molecules are label cDNA. 
     
     
         69 . The method of  claim 64 , wherein the labeled nucleic acid molecules consists of nucleic acid molecules that correspond to HSPG2, CRIP2, TNFRSF14, LOC23117, OBSL1, SLC26A10, PDDC1, RERE, C18orf1, LOC401320, CUGBP2, RBM5, NKTR, SEMA3B, RBMS1, ABCD4, MYH6, MYH7, SFRS16, CA4, EXOSC10, ATXN2L, LTBP4, PTGER3, GPATCH8, LRRC37A, DDX27, SETD5, LONP2, LUC7L, RASA3, MRPS9, RBMS1, CHES1, ZDHHC1, and ARHGAP26.